Emmanuel Papadakis
Stock Analyst at Deutsche Bank
(0.66)
# 3,364
Out of 4,667 analysts
41
Total ratings
33.33%
Success rate
-7.72%
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $102.14 | +46.86% | 9 | Sep 19, 2024 | |
MRNA Moderna | Upgrades: Hold | $85 → $80 | $36.94 | +116.57% | 8 | Aug 6, 2024 | |
GRFS Grifols | Downgrades: Sell | n/a | $8.60 | - | 2 | Mar 12, 2024 | |
AZN AstraZeneca | Downgrades: Hold | n/a | $63.20 | - | 3 | Feb 8, 2024 | |
ALVO Alvotech | Maintains: Hold | $8 → $12 | $12.42 | -3.38% | 2 | Mar 7, 2023 | |
SNY Sanofi | Upgrades: Hold | n/a | $47.78 | - | 4 | Aug 12, 2022 | |
NVO Novo Nordisk | Upgrades: Buy | n/a | $105.27 | - | 4 | Mar 16, 2022 | |
CVAC CureVac | Initiates: Hold | $35 | $2.49 | +1,305.62% | 1 | Oct 22, 2021 | |
NVS Novartis AG | Downgrades: Sell | n/a | $103.09 | - | 3 | Sep 20, 2021 | |
ARGX argenx SE | Initiates: Hold | n/a | $591.82 | - | 1 | Jul 23, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $33.35 | - | 4 | Feb 4, 2021 |
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $102.14
Upside: +46.86%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $36.94
Upside: +116.57%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $8.60
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $63.20
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $12.42
Upside: -3.38%
Sanofi
Aug 12, 2022
Upgrades: Hold
Price Target: n/a
Current: $47.78
Upside: -
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $105.27
Upside: -
CureVac
Oct 22, 2021
Initiates: Hold
Price Target: $35
Current: $2.49
Upside: +1,305.62%
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $103.09
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $591.82
Upside: -
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $33.35
Upside: -